Deferoxamine Mesylate Injection, Powder, Lyophilized, For Solution
NDC 0409-2337
Product Information
Deferoxamine Mesylate is a ANDA-approved product labeled by Hospira, Inc.. This medication is typically used as a iron chelating activity [moa]. It is supplied as a injection, powder, lyophilized, for solution for intramuscular; intravenous; subcutaneous administration. This product entry covers the primary NDC 0409-2337 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
- Intramuscular - Administration within a muscle.
- Intravenous - Administration within or into a vein or veins.
- Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 0409-2337?
What are the uses of this product?
What are Active Ingredients of this product?
- DEFEROXAMINE MESYLATE 2 g/1 - Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- DEFEROXAMINE MESYLATE (UNII: V9TKO7EO6K)
- DEFEROXAMINE (UNII: J06Y7MXW4D) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1731345 - deferoxamine mesylate 2 GM Injection
- RxCUI: 1731345 - deferoxamine mesylate 2000 MG Injection
- RxCUI: 1731350 - deferoxamine mesylate 500 MG Injection
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.